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The eczemas represent a common and diverse group
of inflammatory skin diseases whose definitions and
pathogenic mechanisms have often been confused
and controversial. Since the millennium, fresh ap-
proaches are providing better insight. Research has
focused much more upon the epidermis and the very
relevant signaling pathways that contribute to spon-
giosis, proliferation, generation of proinflammatory
factors, and differentiation to form an effective stratum
corneum barrier. A major step in understanding has
come from the solidly confirmed association between
filaggrin null mutations of ichthyosis vulgaris and atopic
dermatitis. Similar associations relating to protease and
lipid defects have highlighted the role of barrier
disruption that allows greater access of environmental
toxins, microbes, and allergens. Animal models are
beginning to predict mechanisms in which such direct
perturbation of keratinocytes may initiate inflammation
and condition immune responses in irritant contact
dermatitis and atopic dermatitis. These conceptual shifts
are nurturing more balanced approaches to understand-
ing eczema and hold the hope for better prevention
efforts and more specific molecular targeting for therapy.
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INTRODUCTION
Eczema represents a family of inflammatory skin conditions
characterized by pruritic, papulovesicular, sometimes weep-
ing dermatitis. All demonstrate the histological hallmark of
spongiosis, which helps to distinguish the eczemas from
papulosquamous diseases such as psoriasis. Eczema is
probably the most common cutaneous affliction (a partial
list of eczemas is shown in Table 1), with few individuals
escaping at least occasional irritant contact dermatitis.
A large population-based survey in the United States
recorded a prevalence of 10.7% for nonspecific eczema
and 6% for atopic dermatitis (AD) (Hanifin and Reed, 2007).
The term, derived from the Greek, eczeo (‘‘to boil or
effervesce’’), is nicely descriptive of the acute, spongiotic,
sometimes vesicular skin lesions. Eczema and dermatitis are
generally used synonymously, though popular use by patients
and many physicians implies AD. A variety of etiological and
regional variants are included within the eczema family.
Allergic contact dermatitis (ACD), caused by cell-mediated
hypersensitivity to chemical haptens, is relatively well-under-
stood mechanistically. In contrast, irritant contact dermatitis
(ICD) has received far less basic investigation and, although
considerable research has been directed at AD in the past three
decades, the complexities of this disease have defied clear
understanding, allowing only a general description of patho-
genesis. It is an inflammatory skin disease, usually familial,
with complex genetic underpinnings. AD is associated with
defects of the stratum corneum barrier (Elias, 2005; Elias and
Steinhoff, 2008) and it usually predisposes to IgE reactivity. Th2
cells in lymph nodes and peripheral blood are responsible for
elevated serum IgE and increased numbers of eosinophils
(Leung et al., 2004). Circulating peripheral blood Th1 cells in
AD appear to undergo activation-induced cell death (Akdis
et al., 2003), which, along with increased levels of IL-10 and
prostaglandin E2 (Ohmen et al., 1995; Chan et al., 1996) might
account for the apparent Th2 predominance in AD.
The T-cell component in AD skin remains somewhat obscure
and confused. Early studies assumed that IL-4-producing Th2
cells would predominate, yet an initial study comparing AD,
ACD, and tuberculin reactions suggested the opposite, with
relatively greater IFN-g in AD lesional biopsies and more IL-4 in
ACD reactions (Ohmen et al., 1995). Follow-up studies then,
using the aeroallergen patch test as a surrogate for AD, showed
Th2 cells in the early 24-hour reactions and IFN-g-associated
Th1 cells later (Grewe et al., 1995). Other studies attempted to
sample lesional ‘‘acute’’ and ‘‘chronic’’ AD lesions, showing
Th2 and Th1 features, respectively (Hamid et al., 1994), though
acute lesions cannot be induced, thus are necessarily poorly and
variably defined. Histologically, the two stages can show
marked differences in spongiosis and proliferative features, thus
are difficult to blind. ACD controls would provide appropriate
comparisons but have been lacking from most studies. These
technical problems have caused uncertainty as to the role of Th2
in eczematization. Lesional AD skin displays relatively few Th2
cells and clonally expanded T cells isolated from AD skin, or
immunohistochemically characterized in situ, display mixed
Th0/Th1 and Th2 cytokine profiles producing high quantities of
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IFN-g, Fas ligand, tumor necrosis factor-a, IL-5, and IL-13, but
not IL-4 (Akdis et al., 1999; Verhagen et al., 2006). These studies
have helped open the stage to more comprehensive examina-
tions of T cells in AD lesions. Several studies have indicated that
CD8 cells may play a role (Akdis et al., 1999; Hennino et al.,
2007; Oflazoglu et al., 2008) and a recent report presents strong
evidence for predominance of distinct CD8þ T-cell populations
producing IL-13 and IFN-g in AD lesions (Hijnen et al., 2008).
Likewise, studies have suggested increased numbers of IL-17þ
cells in some AD lesions (Koga et al., 2008), though decreased
IL-17 expression has also been reported (Guttman-Yassky et al.,
2008).
Clearly, the cell-mediated aspects of AD remain uncertain.
Atopic diseases in general appear to be associated with
defective cyclic nucleotide regulation of immune and
inflammatory cells (Hanifin and Chan, 1995), but no unified
genetic understanding of the immunological abnormalities
has come forth. The clearly evident fact that in about 20% of
patients, AD occurs in the absence of IgE reactivity or
personal/familial atopy undermines the assumption of a
primary immunological defect. Instead, the recent findings
of a strongly confirmed association between AD and filaggrin
(FLG) null mutations (Palmer et al., 2006; Sandilands et al.,
2007b) suggest the possibility that a barrier defect may be a
major factor, or perhaps a primary cause of Th2/IgE
abnormalities. Interestingly, similar conclusions are begin-
ning to emerge from research in asthma (Holgate, 2007).
These new findings, along with numerous studies indicat-
ing protease, protease inhibitor, and lipid abnormalities in
AD stratum corneum (Elias, 2005; Elias and Steinhoff, 2008),
have firmly focused research upon the epidermis in AD.
Obviously, barrier defects provide greater access for toxins,
microbes, and allergens. A clue to the importance of
transepidermal antigen inoculation in amplifying Th2/IgE
reactivity derives from murine studies (Wang et al., 1996;
Spergel et al., 1998; Herrick et al., 2000) and is supported by
clinical observations (Lack et al., 2003). More recent
approaches demonstrate that epidermal structural defects
may relate to impaired innate immunity and to vitamin
D-enhanced antimicrobial effects (Schauber et al., 2007).
Another realm of investigation is demonstrating a complex
interaction of keratinocyte (KC) signaling events that influ-
ence apoptosis, spongiosis, and inflammation in eczema
(Trautmann et al., 2000; Pastore et al., 2005; Farley et al.,
2006). Spongiosis is perhaps the earliest physical lesion of
AD, and studies suggest it to be the culmination of a varied,
multistep epidermal signaling process. An initial report noted
Fas-mediated KC apoptosis occurring in AD and ACD
(Trautmann et al., 2000), concluding that the process might
result in spongiosis. More recent work has demonstrated
spongiosis to result from protease-induced lysis of cadherins
and probably independently of the apoptosis that leads more
prominently to proliferative and proinflammatory signals
(Farley et al., 2006; Proksch et al., 2006). The proliferative
features have tended to be overlooked in AD, yet may be of
considerable importance and relevance because the licheni-
fication that is so common in AD causes recalcitrance to
topical therapies. Proinflammatory factors derived from KCs
have received considerable attention in recent years—thymic
stromal lymphopoietin, IL-18, RANTES, GM-CSF, and others
may contribute to not only the epidermal inflammation but
also to mast cell reactivity and T-cell-related type 1 and type
2 immune responses (Soumelis et al., 2002; Li et al., 2006;
Liu, 2006; Allakhverdi et al., 2007).
The genetically conferred epidermal barrier defects that
predispose to AD include both Netherton’s syndrome and
ichthyosis vulgaris. Netherton’s is caused by mutations in the
serine protease inhibitor Kazal type 5 gene that codes the
protease inhibitor, lympho-epithelial Kazal-type-related inhibi-
tor, presumably opening the stratum corneum to destructive
intrinsic and microbial proteases (Chavanas et al., 2000). Loss-
of-function FLG mutations underlie the development of
ichthyosis vulgaris (Palmer et al., 2006). A number of such
mutations have now been described in Europeans and Asians
(Sandilands et al., 2007b; Nomura et al., 2008), and multiple
reports have confirmed the predisposition of ichthyosis vulgaris
to development of AD and allergic respiratory disease (Sandi-
lands et al., 2007a). These common FLG mutations can also
combine with other mutations to uncover subclinical genoder-
matoses (Liao et al., 2007) and may well herald future findings of
mutations in other important barrier proteins such as involucrin,
loricrin, and so on. Such possibilities allow speculation as to
whether barrier defects and their downstream immunological
effects might theoretically account for all or the majority of AD
and asthma (Irvine, 2007; Sandilands et al., 2007a).
There have been many reasons for the long-held assumption
of IgE and Th2 primacy in AD, but most are based on correlative
information. A prominent correlation is the high serum IgE with
more severe AD but severity usually reflects more extreme skin
barrier disruption, hence greater inoculation of antigens
triggering Th2 and IgE responses. It appears that T cells are
important in the pathogenesis of eczemas. A recent study raises
the interesting possibility that Th2 cytokines and IFN-g may
affect epidermal differentiation, respectively decreasing or
increasing filaggrin expression (Howell et al., 2007). T cells
appear to be the primary response unit in ACD and it is
reasonable to surmise that they underlie the allergenic reactivity
evident in most AD patients. Alternatively, in AD and irritant
dermatitis, they may simply arrive at the behest of KC factors
such as thymic stromal lymphopoietin (Li et al., 2006). Their
role in AD could be mainly a factor in chronicity (that is,
maintaining inflammation) and in response to infection.
In summary, the conceptual focus is switching from
immunological to epidermal barrier mechanisms that underlie
Table 1. The eczema family
Etiologic/morphologic variants Regional variants
Atopic dermatitis Hand eczema
Contact dermatitis Face/eyelids
Irritant (ICD) Lips (cheilitis)
Allergic (ACD) Scalp
Nummular eczema Diaper dermatitis
Lichen simplex chronicus Stasis dermatitis
www.jidonline.org 321
JM Hanifin
Evolving Concepts of Pathogenesis
AD. There are now well-established genetic associations
between ichthyosis and AD and asthma. Stratum corneum
‘‘bricks and mortar,’’ proteases, their inhibitors, and structural
proteins are all being assessed and may lead to further genetic
associations. These advances suggest that, in the coming
years, genetics may reveal new molecular sites that provide
previously unidentified, specific targets for barrier repair and
for prevention of AD and allergies.
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